Menos de 10 of about 170 vaccine projects against SARS-CoV-2, the virus that causes covid-19, are found in stage 3 of your tests, which defines your success or failure.
“Governments are under pressure to secure supplies for their populations of those that are successful. If governments compete, most countries could be left out, “warns WHO.
So in this race at least 165 countries have expressed interest to be part of a joint understanding that aims to guarantee equitable access to a vaccine that works.
They have named it Covax mechanism.
Until last month 75 of those 165 countries they had raised their hands like financiers development of a “portfolio” of vaccines that have the best chance of success, WHO reported.
Those nations accepted share the potential success of one or more of these vaccineswith other 90 countries with less economic possibilities or weaker health systems. In total, 60% of the world‘s population would have access to vaccination.
For Seth Berkley, Executive Director of the Gavi Foundation – which co-leads the initiative together with the Coalition for Innovations in Epidemic Preparedness (CEPI) and WHO – Covax may be the only truly global solution.
“For the vast majority of countries, whether they can afford their own doses or need assistance, it means receiving a guaranteed share of doses and avoid stay in ethe end of the rowHe said at a WHO assembly.
Argentina, Brazil and Mexico They are among the Latin American countries that have spoken out in favor of the Covax alliance.
However, large economies such as United States, China, the European Union and Russia they indicated that, for the time being, they will not join the coalition.
This raises concerns that the current pandemic will worsen what happened in 2009 with the H1N1 crisis.
On that occasion, some countries were trying to immunize their entire population instead of respecting the international orientation of vaccinating the most vulnerable in all countries.
What are you planning to do?
Vaccine projects that claim to be in advanced stage 3, such as that of Russia, China or the University of Oxford-AstraZeneca – have not yet proven their effectiveness in mass groups.
Even so, several countries have already agreed produce them on a large scale, such as the Argentina-Mexico association to produce and distribute the Oxford-AstraZeneca vaccine in Latin America.
As the experts point out, this is a coin tossAlthough you save time by producing it even without having the results of its effectiveness, you can lose everything if it does not demonstrate its effectiveness in tests.
Faced with this problem, the WHO says that all Covax countries “They will share the risks associated with vaccine development” through the creation of a global financing fund.
On the one hand, they will invest in the advance manufacture of candidate vaccines from their portfolio “as soon as their success is demonstrated”.
On the other, they will join the acquisitions of these vaccines “to achieve sufficient volumes” next year with 2 billion doses that have passed WHO approval.
“Through Covax, our aspiration is power vaccinate the most vulnerable 20% of the population of each participating country, regardless of income level, by the end of 2021, ″ he says Richard Hatchett, CEO of CEPI.
The mechanism seeks to distribute the doses proportionally to the populations of each country, “initially prioritizing health workers and then expanding to cover 20% of the population”
A subsequent round of doses would be established “based on the country’s needs, vulnerability and the threat of covid-19”, in addition to there being a “humanitarian reserve”.
Covax is part of the Covid-19 Tool Access Accelerator, or simply Acelerador ACT, which the WHO created in response to the pandemic.
Soumya Swaminathan, WHO’s chief scientist, says that for it to really work it takes “That all countries support” the initiative.
In July, a consultation process began with the 165 countries that have initially expressed their intention to participate and that will have to provide an advance payment and a commitment to buy doses by the end of August, which will make them part of Covax.
In the first phase, Covax says that requires US $ 2 billion,of which they have already raised US $ 600 million.
WHO Director Tedros Adhanom Ghebreyesus said on August 13 that “Covax already has nine candidate vaccines in its portfolio, which are in phase 2 or 3 trials.”
The International Monetary Fund (IMF), says Tedros, estimates that the pandemic costs the world $ 375 billion and that in two years it will exceed US $ 12 billion, if it doesn’t stop.
“It’s easy to think of the Accelerator as a research and development measure; but in reality it is the best economic stimulus in which the world can invest ”, he points out.
“The sooner we stop the pandemic, the sooner we can ensure that internationally interconnected sectors, such as travel, trade and tourism, can truly recover. There is hope”.